Hengrui Medicine (600276)

Stock Analysis Report　|　Industry: Innovative Drug R&D and Pharmaceuticals　|　Report Date: 2026-10-02　|　Market data as of the 2026-09-30 close

This report was automatically compiled by AI based on public information and is for reference only. It does not constitute investment advice.

Core View: Innovative drug growth remains strong, but adjusted profit weakened in the interim report; valuation at historical lows awaits profit delivery

Market data as of the 2026-09-30 close

1. Key Investment Points

• Interim earnings were stable on the surface, but adjusted profit has weakened: In the 2026 interim report, revenue was RMB 15.456 billion and net profit attributable to shareholders was RMB 4.465 billion, down 1.94% and up 0.34% year over year, respectively; net profit excluding non-recurring items fell 12.71% year over year.
• Innovative drug sales growth is the main growth engine: Innovative drug sales in 2025 were RMB 16.342 billion, up 26.09% year over year; oncology revenue grew 14.29%, while metabolic and cardiovascular revenue grew 39.39%.
• The share price is at a historical valuation low: The closing price on September 30 was RMB 47.20, with PE-TTM of 40.55x and PB-MRQ of 4.86x, at the 6th and 2nd percentiles, respectively, over the past 5.2 years; institutional target prices range from RMB 50 to 87.42.

Market Expectations and Evidence

• What the market is pricing in: The valuation implies average annual EPS growth of approximately 19.3% over the next 10 years, slightly below analysts’ forecast of 20.54% net profit growth in 2026. The time horizons differ, so the two figures are not directly comparable.
• What the evidence shows: Innovative drug sales grew 26.09% in 2025, supporting medium-term growth expectations. However, adjusted profit fell in the 2026 interim report, with revenue and adjusted profit for the quarter included in the reporting period down 14.50% and 35.37%, respectively, indicating short-term pressure on earnings delivery. The HRS-1596 licensing deal remains at an early clinical stage, and milestone payments are not yet realized revenue.

Evidence balance: Even; confidence: High (covered by 27 institutions; market data and financial figures programmatically cross-checked)

Growth in innovative drug sales and a low historical valuation provide support, but weaker adjusted profit in the interim report and deteriorating quarterly performance mean that near-term earnings delivery remains to be verified.

2. Business and Competitive Strengths

2.1 Business Mix

The company sells drugs to patients and medical institutions and generates revenue through out-licensing and other means; growth is driven mainly by innovative drug sales and product mix.

2.2 Competitive Strengths

Strength of competitive advantages: Moderate

• R&D investment scale: R&D investment in 2025 was RMB 8.724 billion, or 27.58% of revenue
• Innovative product pipeline: 24 Category 1 innovative drugs have been approved, and more than 100 proprietary innovative products are in clinical development
• Commercialization base: Innovative drug sales in 2025 were RMB 16.342 billion, up 26.09% year over year

Key threats: R&D failures or delays, target homogeneity, pressure from reimbursement and hospital access, and price cuts for mature products under volume-based procurement could all weaken product returns.

2.3 Value-Chain Position and Profitability Trends

• In 2025 pharmaceutical manufacturing costs, raw materials and packaging totaled RMB 2.633 billion, or 62.92%; labor and manufacturing expenses totaled RMB 1.551 billion, or 37.08%.
• Purchases from the top five suppliers totaled RMB 1.280 billion, or 26.61% of annual procurement; specific material categories were not further broken down, and there is no evidence of bargaining advantages for key raw materials.
• Products are sold to patients through medical institutions and other channels; the 2025 annual report disclosed that sales to the top five customers accounted for 55.72% of total annual sales, but did not disclose customer names.
• Reimbursement negotiations, volume-based procurement, and hospital access restrictions constrain prices for some drugs; clinically differentiated innovative drugs have some pricing latitude, but remain subject to reimbursement and competition.
• The 2025 annual report disclosed that the top five customers accounted for 55.72% of sales; customer names were not disclosed, and the figure is not directly comparable with the basis used in the 2022 audit report.
• At the end of 2025, accounts receivable totaled approximately RMB 5.219 billion, equivalent to 16.5% of revenue and 67.7% of net profit attributable to shareholders; turnover was approximately 59 days based on the average of year-end balances.

Hengrui operates in the relatively high-value-added areas of innovative drug R&D and brand commercialization, while also retaining manufacturing and mature-product businesses. Margin improvement depends on innovative drug sales growth, product-mix upgrades, conversion of out-licensing deals, and cost efficiency.

2.4 Industry and Peer Comparison

Commercialization of innovative drugs and out-licensing have become important growth sources for Hengrui. Reimbursement negotiations, volume-based procurement, and hospital access continue to affect pricing and sales growth, making the efficiency of converting R&D results into commercial products critical.

Hengrui’s innovative drug sales in 2025 were RMB 16.342 billion, and R&D investment was 27.58% of revenue. Its R&D pipeline and presence across multiple therapeutic areas are notable strengths. Its weakness is that returns on R&D investment still depend on clinical outcomes, reimbursement access, and commercial sales growth; mature products are also affected by price cuts under volume-based procurement.

3. Financial Quality

3.1 Operating Performance

Amounts are in RMB billions; the latest reporting period is the 2026 interim report, and annual data are from the 2025 and 2024 annual reports.

Net profit attributable to shareholders increased slightly in the interim report, while adjusted net profit declined, indicating support from non-recurring gains and losses. In the quarter included in the interim report, revenue fell 14.50% year over year and adjusted net profit fell 35.37%, indicating a more pronounced weakening in performance.

3.2 Financial Health Check

4. Valuation and Market Expectations

4.1 Valuation

Valuation multiples are calculated programmatically using closing data as of 2026-09-30 (trailing 12-month basis); peer multiples are calculated on the same basis using closing data as of 2026-09-30.

Market-implied expectations: At the current PE of 40.55x, if investors require an annualized return of 8% and the stock is valued at 15x earnings in 10 years, EPS would need to grow at an average annual rate of approximately 19.3% (excluding dividends; a conservative assumption). This can be compared with the institutional growth forecasts below.

PE-TTM of 40.55x, PB-MRQ of 4.86x, and PS-TTM of 10x are at the 6th, 2nd, and 16th percentiles, respectively, over the past 5.2 years, all below their historical medians of 55.89x, 6.87x, and 11.75x. The share price implies average annual EPS growth of approximately 19.3% over the next 10 years, close to—but over a different time horizon from—the institutional forecast of 20.54% net profit growth in 2026. Valuation is at a historical low, but still depends on continued innovative drug sales growth and profit delivery.

4.2 Consensus Estimates

As of 2026-10-02, 27 institutions had issued ratings in the past six months; forecasts are institutional averages. The 2026E net profit forecast range from 20 institutions is RMB 8.433–10.810 billion.

4.3 Institutional Views

The average target price from 8 institutions is RMB 70.89, with a range of RMB 50–87.42; the most recent is RMB 62.75 from CICC on 2026-09-30.

5. Catalysts and Recent Events

5.1 Upcoming Key Milestones

5.2 Recent Important Events

• 2026-09-29 HRS-1596 licensed to Novo Nordisk outside Greater China (Positive): Novo Nordisk obtained exclusive rights to develop, manufacture, and commercialize the drug outside Greater China, with an upfront payment of USD 300 million, potential total payments of up to USD 2.6 billion, and additional sales royalties. HRS-1596 remains at an early clinical stage, and milestone payments are not realized revenue. The company disclosed on September 22 that the drug had received authorization to begin Phase I clinical trials in China.
• 2026-07 Camrelizumab U.S. filing receives a CRL (Negative): The U.S. biologics license application for camrelizumab plus apatinib as first-line treatment for liver cancer received a complete response letter from the FDA, meaning that the application was not approved at that time. The timing of remedial work and resubmission remains unclear.
• 2026-09-18 New A-share buyback underway (Neutral): The company plans to repurchase RMB 1–2 billion of shares using its own funds for an A-share employee stock ownership plan. As of the first buyback announcement, 335,000 shares had been repurchased for RMB 14.5036 million; the program is still at an early implementation stage and is not a capital reduction through cancellation.
• 2026-09-15 Marketing application for SHR-2004 accepted (Positive): The marketing application for SHR-2004, a monoclonal antibody against coagulation factor XI for the prevention of venous thrombosis after knee replacement surgery, has been accepted and entered the review stage. Acceptance does not mean approval for marketing or revenue generation.

6. Bull-Bear Debate and Risks

6.1 Bull Case

• Innovative drug sales in 2025 were RMB 16.342 billion, up 26.09%; oncology innovative drugs accounted for 81.02% of innovative drug sales.
• R&D investment was RMB 8.724 billion, or 27.58% of revenue; 24 Category 1 innovative drugs have been approved, and more than 100 proprietary innovative products are in clinical development.

6.2 Bear Case

• In the quarter included in the interim report, revenue fell 14.50% year over year and adjusted net profit fell 35.37%, indicating a marked weakening in earnings momentum.
• Camrelizumab’s U.S. filing received a complete response letter from the FDA, with the timing of remedial work and resubmission still unclear.
• Net operating cash flow / net profit was 0.44 in the interim report, while inventory turnover days rose to 250.1, putting pressure on cash conversion and inventory efficiency.

6.3 Other Risks

• The top five customers accounted for 55.72% of sales, but their names were not disclosed; changes in procurement by major customers could affect revenue and collections.
• Reimbursement negotiations, volume-based procurement, and hospital access constrain drug prices. If mature products face price cuts faster than innovative drugs grow sales, profit margins could come under pressure.
• R&D failures, delays, or target homogeneity could reduce commercial returns on products and weaken the market’s valuation of the R&D pipeline.

7. Monitoring Checklist

8. Share Price and Short-Term Outlook (Next Week, Scenario Analysis, for Reference Only)

⚠️ The scenario weights below are subjective, heuristic assessments based on current technical and fund-flow conditions, not statistical probabilities; short-term volatility risk is high.

8.1 Technical Overview

The share price has rebounded to near the upper Bollinger Band and the 20-day high. Short-term moving averages and MACD momentum have improved, but RSI6 is elevated and the price remains capped by the MA60. The latest trading volume was 1.82x the 20-day average, while net inflows from major investors were RMB 694 million on the day; this reflects only a single trading session.

8.2 Key Price Levels

8.3 One-Week Range Based on Historical Volatility

Using the 2026-09-30 price of RMB 47.20 as the baseline, the closing price range for the next five trading days is estimated from the return distribution over the past 300 trading days (scaled using the current index-weighted daily volatility of approximately 2.1%, while retaining this stock’s own frequency of large gains and losses):

This range reflects only the stock’s recent volatility and does not indicate the direction of price movement; actual performance may exceed the range in response to major announcements or a sharp market decline.

8.4 Scenarios for the Coming Week (Subjective Weights, Not Statistical Probabilities)

• Consolidation (relatively higher weight, approximately 50%): Trading within RMB 44.81–47.50; an advance may fail to hold above the upper band on increased volume, or the price may pull back to the moving averages and find support. Based on historical volatility, the probability of the closing price one week later falling within this range is approximately 50%.
• Downside bias (moderate weight, approximately 30%): A break below RMB 44.81 followed by a failed recovery could lead to a test of the RMB 41.89–42.12 support zone. Based on historical volatility, the probability of the closing price one week later falling within this range is approximately 15%.
• Stronger rebound (lower weight, approximately 20%): If trading value expands and the share price closes and holds above RMB 47.50, watch for a move toward the MA60 near RMB 50.03. Based on historical volatility, the probability of the closing price one week later falling within this range is approximately 30%.

The weights in parentheses are subjective; the probabilities at the end of each sentence are inferred from the volatility ranges above and reflect volatility only, not direction.

8.5 Fund Flows and Liquidity

Over the past 10 trading days (2026-09-16 to 09-30), daily trading value was approximately RMB 1.528–5.200 billion and turnover was approximately 0.55%–1.79%; the latest trading value was RMB 5.235 billion and turnover was 1.76%. As of 2026-08-19, the top 10 holders of tradable shares collectively held 55.32%; E Fund, China Universal, and Invesco Great Wall fund products together held 2.05%. Shareholder data are disclosed with a lag, and the ownership structure may have changed. Trading is active but daily volumes vary considerably, so investors should remain mindful of market impact.

If trading value exceeds the upper end of the past 10-day range, approximately RMB 5.2 billion, for two consecutive days and the share price closes and holds above RMB 47.50, this could serve as confirmation of a volume-price breakout.

The scenario analysis above is based on closing data as of 2026-09-30 and calculations using historical prices and technical indicators. Short-term share-price movements may also be affected by news, fund flows, broader market conditions, and other factors. Technical indicators are inherently lagging and limited; this analysis does not guarantee future performance or constitute a buy or sell recommendation. Please make an independent assessment based on the latest market information and assume your own investment risk.

Sources

• 江苏恒瑞医药股份有限公司2025年年度报告
• 恒瑞医药(600276)_公司公告_恒瑞医药：2025年年度报告摘要新浪财经_新浪网
• 恒瑞医药(600276)_公司公告_恒瑞医药：2025年年度报告新浪财经_新浪网
• 恒瑞医药
• hkexnews.hk（公告PDF）
• 恒瑞医药(600276)_公司公告_恒瑞医药：恒瑞医药2021年年度报告新浪财经_新浪网
• static.cninfo.com.cn（公告PDF）
• 恒瑞医药(600276)_公司公告_恒瑞医药：2023年年度报告新浪财经_新浪网
• 东方财富 F10 财务分析
• 东方财富 F10 盈利预测
• 恒瑞医药:恒瑞医药2026年半年度报告
• static.cninfo.com.cn（公告PDF）
• static.cninfo.com.cn（公告PDF）
• static.cninfo.com.cn（公告PDF）
• 恒瑞医药
• 恒瑞医药(600276)_公司公告_恒瑞医药：收到关于注射用卡瑞利珠单抗的完整回复信的公告新浪财经_新浪网
• 恒瑞医药:恒瑞医药2026年第一次临时股东会决议公告 _ 恒瑞医药(600276) _ 公告正文
• 江苏恒瑞医药股份有限公司关于与Novo Nordisk A/S签署HRS-1596项目授权许可协议的公告|上海证券报
• 证券代码：600276　　证券简称：恒瑞医药　　公告编号：临2025-173
• 东方财富 个股资金流向
• 东方财富 股东研究

This report was automatically researched, compiled, and generated by AI based on publicly available sources. Information is current as of the 2026-09-30 close and may not reflect the latest developments. Please refer to the company’s official announcements and authoritative data terminals for specific figures. This report is for information and research reference only and does not constitute investment advice. Investors should make their own independent judgments and assume their own investment risk.